Preparation method for formamide compounds
By optimizing the reaction conditions in the presence of carbon monoxide, palladium catalyst and R4-NH2, the problems of high catalyst dosage and difficult to control in the preparation method of formamide compounds in the prior art are solved, and the yield and reaction efficiency of compound 7a are improved , achieving a more efficient preparation process.
Patent Information
- Application Number
- PCT/CN2024/097931
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-08
- Filing Date
- 2024-06-07
- Publication Date
- 2024-12-12
AI Technical Summary
The existing preparation methods for formamide compounds have problems such as high dosage, low yield and difficult to control the reaction catalyst, which affects the effective preparation of compound 8.
Compound 7a was prepared by reacting carbon monoxide, palladium catalyst and R4-NH2 under specific conditions. The reaction efficiency and yield were improved by optimizing the molar ratio of palladium catalyst and phosphine ligand, the selection of base, and the use of reaction temperature and solvent.
The yield of compound 7a is significantly improved, the controllability of reaction temperature is achieved, the amount of catalyst is reduced, and the subsequent treatment and purification process is simplified.
Smart Images

Figure CN2024097931_12122024_PF_FP_ABST
Abstract
Description
A preparation method of formamide compounds Technical Field
[0001] The present invention belongs to the field of medicine and relates to a method for preparing a formamide compound. Background Art
[0002] Poly(ADP-ribose) polymerase 1 (PARP1) was first described over 50 years ago and has since been found to play a crucial role in DNA repair, maintaining genomic integrity, and regulating various metabolic and signal transduction processes. PARP1 catalyzes the transfer of an ADP-ribose residue from NAD+ to its target substrate, forming a poly(ADP-ribose) (PAR) chain. PAR chain formation and clearance occurs in nearly all eukaryotic cells.
[0003] ADP-ribosylation is a post-translational modification of proteins that is widely present in various physiological and pathological processes. It refers to the incorporation of one or more ADP-ribose units into specific sites on proteins under the catalysis of enzymes. PARP1 is the first member of the PARP superfamily, which consists of proteins with homology to PARP1. There are currently 17 members, of which 4 (PARP1, PARP2, PARP5A and PARP5B) can synthesize PAR chains. Most other enzymes in the family can only build a single ADP-ribose unit and are therefore classified as mono(ADP-ribosyl)ases (MARs), i.e.
[0004] WO2022247816A discloses the following synthetic route for formamide compounds, using compound 8a as the starting material and obtaining compound 8 through six steps with an overall yield of 2.7%.
[0005] Summary of the Invention
[0006] In a first aspect, the present disclosure provides a method for preparing a compound as shown in Formula 7a or a pharmaceutically acceptable salt thereof, which has the advantages of low catalyst usage, improved yield, and controllable reaction temperature. The method comprises reacting a compound as shown in Formula 5a or a pharmaceutically acceptable salt thereof in the presence of carbon monoxide, a palladium catalyst, and R4-NH2 to obtain a compound as shown in Formula 7a or a pharmaceutically acceptable salt thereof.
[0007] Wherein, R1 is an amino protecting group;
[0008] R2 is selected from halogen;
[0009] R3 is selected from halogen;
[0010] R4 is selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl;
[0011] Each R5 is independently selected from halogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxy, cyano, oxo;
[0012] Each R6 is independently selected from halogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxy, cyano;
[0013] n is an integer selected from 0 to 6;
[0014] m is an integer selected from 0-2.
[0015] In some embodiments, as described in the preparation method of the first aspect, n is selected from 0, 1, 2, 3, and 4, preferably n is selected from 0, 1, and 2, and more preferably n is selected from 0 and 1.
[0016] In some embodiments, in the preparation method described in the first aspect, m is selected from 0 and 1.
[0017] In some embodiments, as described in the preparation method of the first aspect, R2 is selected from fluorine, chlorine, bromine, and iodine, and preferably R2 is bromine.
[0018] In some embodiments, as described in the preparation method of the first aspect, R3 is selected from fluorine, chlorine, bromine, and iodine, and preferably R3 is chlorine.
[0019] In some embodiments, in the preparation method as described in the first aspect, the palladium catalyst is selected from a divalent palladium catalyst.
[0020] In some embodiments, as described in the preparation method of the first aspect, the palladium catalyst is selected from palladium acetate, palladium dichloride, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, palladium trifluoroacetate, palladium pivalate, tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium chloride, bis(benzonitrile)palladium chloride, and bis(acetonitrile)palladium chloride.
[0021] In some embodiments, in the preparation method described in the first aspect, the palladium catalyst is selected from palladium acetate.
[0022] In some embodiments, according to the preparation method of the first aspect, the molar ratio of the compound represented by Formula 5a to the palladium catalyst is 1:0.1 to 1:0.0001; preferably 1:0.01 to 1:0.0005; more preferably 1:0.01 to 1:0.001; and most preferably 1:0.005.
[0023] In some embodiments, according to the preparation method of the first aspect, the compound represented by Formula 5a or a pharmaceutically acceptable salt thereof is reacted in the presence of a phosphine ligand to obtain the compound represented by Formula 7a or a pharmaceutically acceptable salt thereof.
[0024] In some embodiments, as described in the preparation method of the first aspect, the phosphine ligand is selected from triphenylphosphine, tri(o-methylphenyl)phosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2'-methylbiphenyl, 2-(di-tert-butylphosphino)-2'-methylbiphenyl, 1,1'-bis(diphenylphosphino)ferrocene, (±)-2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl, 4,5-bisdiphenylphosphino-9,9-dimethylxanthene, bis(2-diphenylphosphinophenyl)ether, 2-dicyclohexylphosphino-2',6'-diisopropylbiphenyl, 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)- 1,1'-biphenyl]-2-yl)phosphine, [(4-(N,N-dimethylamino)phenyl]di-tert-butylphosphino]biphenyl, 2-di-tert-butylphosphino-2'-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 2-(di-tert-butylphosphino)-3,6-dimethoxy-2'-4'-6'triisopropyl-1,1'-biphenyl, dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine, [(4-(N,N-dimethylamino)phenyl]di-tert-butylphosphino, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropylbiphenyl, 1,2-bis(diphenylphosphino)ethane, 1,3-bis(diphenylphosphino)propane, 1,4-bis(diphenylphosphino)butane.
[0025] In some embodiments, in the preparation method according to the first aspect, the phosphine ligand is selected from 1,1'-bis(diphenylphosphino)ferrocene.
[0026] In some embodiments, as described in the preparation method of the first aspect, the molar ratio of the compound represented by Formula 5a to the phosphine ligand is 1:0.1 to 1:0.0001; preferably 1:0.01 to 1:0.0005; more preferably 1:0.01 to 1:0.001; most preferably 1:0.005.
[0027] In some embodiments, according to the preparation method of the first aspect, the compound represented by Formula 5a or a pharmaceutically acceptable salt thereof is reacted in the presence of a base to obtain the compound represented by Formula 7a or a pharmaceutically acceptable salt thereof.
[0028] In some embodiments, according to the preparation method of the first aspect, the base is selected from sodium hydroxide, sodium carbonate, cesium carbonate, triethylamine, sodium acetate or pyridine.
[0029] In some embodiments, according to the preparation method of the first aspect, the base is sodium acetate.
[0030] In some embodiments, according to the preparation method of the first aspect, the molar ratio of the compound represented by Formula 5a to the base is 1:5 to 1:0.5, preferably 1:5 to 1:1, more preferably and most preferably 1:2.
[0031] In some embodiments, the preparation method as described in the first aspect is carried out in a solvent, and the solvent includes but is not limited to one or more of a halogenated hydrocarbon solvent, a nitrile solvent, an amide solvent, and a sulfoxide solvent.
[0032] In some embodiments, the preparation method as described in the first aspect is carried out in a solvent, and the solvent includes but is not limited to one or more of dichloromethane, methanol, ethanol, N,N-dimethylformamide, and N,N-dimethylacetamide.
[0033] In some embodiments, the preparation method as described in the first aspect is carried out in a solvent, and the solvent is methanol and N,N-dimethylformamide.
[0034] In some embodiments, as described in the preparation method of the first aspect, the R4 is selected from C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl.
[0035] In some embodiments, as described in the preparation method of the first aspect, R4 is selected from methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, halomethyl, haloethyl, halopropyl, and halobutyl.
[0036] In some embodiments, according to the preparation method of the first aspect, R4 is methyl.
[0037] In some embodiments, as described in the preparation method of the first aspect, the R1 is selected from C1 to C6 alkyl acyl, C6 to C 10 Aryl acyl, C1~C6 alkylsulfonyl, C6~C 10 Arylsulfonyl, C1-C6 alkoxycarbonyl, C6-C10 Aryloxycarbonyl, substituted or unsubstituted C7~C 12 benzyl.
[0038] In some embodiments, as described in the preparation method of the first aspect, R1 is selected from formyl, acetyl, benzoyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn).
[0039] In some embodiments, according to the preparation method of the first aspect, R1 is tert-butyloxycarbonyl (Boc).
[0040] In some embodiments, the preparation method according to the first aspect can be reacting a compound as shown in Formula 5b or a pharmaceutically acceptable salt thereof to obtain a compound as shown in Formula 7b or a pharmaceutically acceptable salt thereof,
[0041] In some embodiments, the preparation method according to the first aspect can be reacting the compound shown in Formula 5 or a pharmaceutically acceptable salt thereof to obtain the compound shown in Formula 7 or a pharmaceutically acceptable salt thereof.
[0042] In some embodiments, the preparation method as described in the first aspect further comprises adding an organic acid after the reaction is completed, wherein the organic acid is selected from formic acid, acetic acid, and p-toluenesulfonic acid.
[0043] In some embodiments, the preparation method as described in the first aspect further comprises adding an organic acid after the reaction is completed, wherein the organic acid is p-toluenesulfonic acid. By adding an organic acid to form a corresponding salt, the crystallinity of the product can be increased, impurities and catalyst ligands generated during the reaction can be removed, and post-processing and purification can be facilitated. Conversion from the salt form to the free state can be carried out in a manner well known to those skilled in the art, for example, using an appropriate base, including but not limited to sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium bicarbonate, potassium carbonate, potassium hydroxide, etc.
[0044] In a second aspect, the present disclosure further provides a method for preparing a compound as shown in Formula 8a or a pharmaceutically acceptable salt thereof, comprising: reacting a compound as shown in Formula 7a or a pharmaceutically acceptable salt thereof to obtain a compound as shown in Formula 8a or a pharmaceutically acceptable salt thereof,
[0045] wherein R1, R3, R4, R5, R6, n, and m are as defined in the first aspect.
[0046] In some embodiments, the preparation method as described in the first or second aspect, wherein each R5 is independently selected from C 1-6 Alkyl, hydroxy C1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy.
[0047] In some embodiments, the preparation method as described in the first or second aspect, wherein each R5 is independently selected from halogen, hydroxyl, cyano, and oxo.
[0048] In some embodiments, the preparation method as described in the first or second aspect, wherein each R5 is independently selected from C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl.
[0049] In some embodiments, the preparation method as described in the first or second aspect, wherein each R6 is independently selected from halogen, hydroxyl, and cyano.
[0050] In some embodiments, the preparation method of the first or second aspect, wherein each R6 is independently selected from C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy.
[0051] In some embodiments, the preparation method of the first or second aspect, wherein each R6 is independently selected from C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl.
[0052] In some embodiments, the preparation method according to the second aspect comprises reacting a compound as shown in Formula 7b or a pharmaceutically acceptable salt thereof to obtain a compound as shown in Formula 8b or a pharmaceutically acceptable salt thereof,
[0053] In some embodiments, the preparation method according to the second aspect comprises reacting the compound represented by Formula 7 or a pharmaceutically acceptable salt thereof to obtain the compound represented by Formula 8 or a pharmaceutically acceptable salt thereof,
[0054] In some embodiments, the preparation method as described in the second aspect comprises the preparation method of the compound represented by Formula 7a, 7b or 7 or a pharmaceutically acceptable salt thereof as described in the first aspect.
[0055] In some embodiments, the preparation method as described in the second aspect, wherein the preparation method is carried out in the presence of a palladium catalyst, a phosphine ligand, and a base.
[0056] In some embodiments, the preparation method as described in the second aspect, wherein,
[0057] The palladium catalyst can be selected from tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, palladium acetate, palladium chloride, bis(acetonitrile)palladium chloride, bis(benzonitrile)palladium chloride, chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II), (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(II) chloride methyl tert-butyl ether complex, methanesulfonic acid(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II),
[0058] The phosphine ligand can be selected from 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl, tri-tert-butylphosphine, tricyclohexylphosphine, 2-dicyclohexylphosphino-2'-methylbiphenyl, 2-(di-tert-butylphosphino)-2'-methylbiphenyl, 1,1'-bis(diphenylphosphino)ferrocene, (±)-2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl, 4,5-bisdiphenylphosphino-9,9-dimethylxanthene, bis(2-diphenylphosphinophenyl)ether, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)-2'-methylbiphenyl phosphine) biphenyl, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 2-(di-tert-butylphosphino)-3,6-dimethoxy-2'-4'-6'-triisopropyl-1,1'-biphenyl, dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine, [(4-(N,N-dimethylamino)phenyl]di-tert-butylphosphine, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropylbiphenyl,
[0059] The base can be selected from cesium carbonate, potassium carbonate, potassium phosphate, sodium tert-butoxide, sodium tert-amylate, potassium tert-butoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, and cesium hydroxide.
[0060] In some embodiments, according to the preparation method of the second aspect, the molar ratio of the compound of Formula 7a to the palladium catalyst is selected from 1:0.1 to 1:0.001, preferably the molar ratio is selected from 1:0.1 to 1:0.005, and more preferably the molar ratio is selected from 1:0.1 to 1:0.01;
[0061] The molar ratio of the palladium catalyst to the phosphine ligand is selected from 1:10 to 1:0.1, preferably the molar ratio is selected from 1:5 to 1:0.1, and more preferably the molar ratio is selected from 1:5 to 1:1.
[0062] In some embodiments, the preparation method as described in the second aspect is carried out under an inert gas atmosphere, preferably under a nitrogen atmosphere or an argon atmosphere.
[0063] In some embodiments, the preparation method as described in the second aspect comprises the step of reacting the compound represented by Formula 5a or a pharmaceutically acceptable salt thereof to obtain the compound represented by Formula 7a or a pharmaceutically acceptable salt thereof.
[0064] In a third aspect, the present disclosure further provides a method for preparing a compound as shown in Formula 11a or a pharmaceutically acceptable salt thereof, which comprises:
[0065] (1) preparing the compound shown in 8a or a pharmaceutically acceptable salt thereof according to the preparation method described in the second aspect;
[0066] (2) using the compound represented by Formula 8a or a pharmaceutically acceptable salt thereof to prepare the compound represented by Formula 11a or a pharmaceutically acceptable salt thereof;
[0067] wherein R1, R4, R5, R6, n, and m are as defined in the first aspect;
[0068] R7 is selected from halogen;
[0069] R8 is selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, preferably R8 is selected from methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, halomethyl, haloethyl, halopropyl, halobutyl.
[0070] In a fourth aspect, the present disclosure further provides a method for preparing a compound as shown in Formula 11b or a pharmaceutically acceptable salt thereof, comprising:
[0071] (1) preparing the compound shown in 8b or a pharmaceutically acceptable salt thereof according to the preparation method described in the second aspect;
[0072] (2) using the compound of Formula 8b or a pharmaceutically acceptable salt thereof to prepare the compound of Formula 11b or a pharmaceutically acceptable salt thereof;
[0073] In a fifth aspect, the present disclosure further provides a method for preparing a compound as shown in Formula 11 or a pharmaceutically acceptable salt thereof, comprising:
[0074] (1) preparing the compound shown in 8 or a pharmaceutically acceptable salt thereof according to the preparation method described in the second aspect;
[0075] (2) using the compound represented by Formula 8 or a pharmaceutically acceptable salt thereof to prepare the compound represented by Formula 11 or a pharmaceutically acceptable salt thereof;
[0076] In some embodiments, the compound of Formula 11 or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is a fumarate.
[0077] On the other hand, the preparation method disclosed herein further comprises one or more steps of filtration, concentration, purification by column chromatography and drying.
[0078] The terms "form" and "convert" in this disclosure do not necessarily imply a single-step conversion reaction between two substrates; they may be a single-step or multi-step reaction between two substrates. If an intermediate contains a protecting group, the intermediate is subjected to a one-step removal of the protecting group and then reacted with the corresponding substrate to obtain the corresponding target product.
[0079] The numerical values in this disclosure are instrumental measurements and are subject to a certain degree of error. Generally speaking, within a reasonable error range of plus or minus 10%. The context in which the numerical value is used must be considered. For example, the particle size of an active ingredient, where the error after measurement does not exceed plus or minus 10%, may be plus or minus 9%, plus or minus 8%, plus or minus 7%, plus or minus 6%, plus or minus 5%, plus or minus 4%, plus or minus 3%, plus or minus 2%, or plus or minus 1%, preferably plus or minus 5%.
[0080] The salt of the compound described in the present disclosure can be selected from inorganic salts or organic salts. Including "acid" addition salts and "base" addition salts. For example, the salt formed by the acid-base reaction with the basic group (amino group), the acid includes an organic acid or an inorganic acid. In some embodiments, the salt of the compound shown in Formula 7a is p-toluenesulfonate. In some embodiments, the salt of the compound shown in Formula 9 is hydrochloride, and the salt of the compound shown in Formula 11 is fumarate.
[0081] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations.
[0082] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including alkyl groups having 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl. Alkyl groups can be optionally substituted or unsubstituted.
[0083] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0084] The term "amino" refers to -NH2.
[0085] The term "hydroxy" refers to an -OH group.
[0086] The term "mercapto" refers to a -SH group.
[0087] The term "carboxy" refers to -C(O)OH.
[0088] When the functional groups disclosed herein are substituted, the substituents are preferably one or more of the following groups, such as halogen, oxo, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 cycloalkyl.
[0089] "Amino protecting group" is a suitable amino protecting group known in the art, see the literature ("Protective Groups in Organic Synthesis", 5 Th .Ed.TWGreene & P.GMWuts) in the amino protecting group, preferably, the amino protecting group can be (C1~C 10 Alkyl or aromatic) acyl, for example: formyl, acetyl, benzoyl, etc.; can be (C1 ~ C6 alkyl or C1 ~ C 10 Aryl)sulfonyl; It can also be (C1~C6 alkoxy or C1~C 10 It can also be a substituted or unsubstituted alkyl group, such as trityl (Tr), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn). DETAILED DESCRIPTION
[0090] The present disclosure is further described below with reference to examples, but these examples are not intended to limit the scope of the present disclosure.
[0091] Example
[0092] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), or deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.
[0093] MS measurements were performed using an Agilent 1200 / 1290 DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS), a Waters ACQuity UPLC-QD / SQD (manufacturer: Waters, MS model: Waters ACQuity Qda Detector / Waters SQ Detector), and a THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive).
[0094] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489 liquid chromatographs.
[0095] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.
[0096] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.
[0097] Silica gel column chromatography generally uses Yantai Huanghai 200-300 mesh silica gel as the carrier.
[0098] The known starting materials disclosed herein can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui Chemicals, and other companies.
[0099] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.
[0100] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1 L.
[0101] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
[0102] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.
[0103] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0104] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0105] The reaction progress in the examples was monitored by thin layer chromatography (TLC). The developing solvent used in the reaction, the column chromatography eluent system used for purifying the compound, and the developing solvent system for thin layer chromatography included: A: dichloromethane / methanol system. The volume ratio of the solvent was adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.
[0106] Example 1 Preparation of (3,6-dichloropyridin-2-yl)methanol (Compound 2)
[0107] Compound 1 (57.6 g, 0.3 mol, 1.0 eq.) and ethylene glycol dimethyl ether (400 mL, 7 V) were added to a flask, cooled with ice water, and N-methylmorpholine (38.23 g, 0.378 mol, 1.26 eq.) and isobutyl chloroformate (51.22 g, 0.375 mol, 1.25 eq.) were added dropwise. The mixture was stirred and filtered. The filtrate was designated Solution A. In a separate flask, water (375 mL, 6.5 V), ethylene glycol dimethyl ether (375 mL, 6.5 V), and sodium borohydride (25.31 g, 0.669 mol, 2.23 eq.) were added dropwise to the mixture. Solution A was added dropwise and stirred until the reaction was complete. Water and ethyl acetate were added, and the organic phase was separated, dried, and concentrated to obtain 53.5 g of Compound 2 as a yellow oil with a yield of 100% and a purity of 96.4%.
[0108] Example 2 Preparation of 6-bromo-2-(bromomethyl)-3-chloropyridine (Compound 3)
[0109] Compound 2 (52.0 g, 0.292 mol, 1.0 eq.) and 33% hydrobromic acid in acetic acid (501.4 g, 2.05 mol, 7 eq.) were added to a flask and heated to 105-110°C. HPLC analysis was performed to determine complete conversion of the starting material. The mixture was cooled to room temperature, water was added, and the mixture was filtered and dried to yield 75.6 g of compound 3, with a yield of 90.7% and a purity of 98.02%.
[0110] Example 3 Preparation of tert-butyl (R)-3-(((6-bromo-3-chloropyridin-2-yl)methoxy)methyl)piperazine-1-carboxylate (Compound 5)
[0111] In a flask, compound 3 (31.83 g, 147.18 mmol, 1.2 eq.) was dissolved in tetrahydrofuran (350 mL, 10 V) and cooled with ice water. 60% sodium hydride (7.36 g, 183.98 mmol, 1.5 eq.) was added and stirred until uniform. A solution of compound 4 (35.00 g, 122.65 mmol, 1.0 eq.) in tetrahydrofuran (175 mL, 5 V) was added dropwise and stirred until the reaction was complete. Saturated aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate and concentrated to obtain 44.04 g of compound 5 in an 85.3% yield.
[0112] Example 4 Preparation of (R)-tert-butyl 3-(((3-chloro-6-(methylcarbamoyl)pyridin-2-yl)methoxy)methyl)piperazine-1-carboxylate 4-methylbenzenesulfonate (Compound 6)
[0113] In a pressure bottle, compound 5 (38.8 g, 92.22 mmol, 1.0 eq.) was dissolved in N,N-dimethylacetamide (194 mL, 5 V) and methanol (194 mL, 5 V). Palladium acetate (104 mg, 0.461 mmol, 0.005 eq.), 1,1'-bis(diphenylphosphino)ferrocene (256 mg, 0.461 mmol, 0.005 eq.), sodium acetate (15.13 g, 184.4 mmol, 2.0 eq.), and 30% ethanolic methylamine were added. The reaction was stirred at 90-100°C in the presence of carbon monoxide until complete. Saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate. 4-Methylbenzenesulfonic acid monohydrate was added to the organic phase, which was stirred, filtered, and dried to obtain 44.80 g of compound 6, with a yield of 85% and a purity of 98.3%.
[0114] Example 5 Preparation of (R)-tert-butyl 3-(((3-chloro-6-(methylaminoformyl)pyridin-2-yl)methoxy)methyl)piperazine-1-carboxylate (Compound 7)
[0115] In a flask, compound 6 (26.0 g, 45.53 mmol, 1.0 eq.) and ethyl acetate (130 mL, 5 V) were added and stirred evenly. Saturated sodium bicarbonate (78 mL, 3 V) was added in batches to dissolve and clarify. The organic phase was separated and concentrated to obtain 17.6 g of compound 7 with a yield of 96.92% and a purity of 96.7%.
[0116] Example 6 Preparation of (R)-9-(methylaminoformyl)-1,2,4a,5-tetrahydro-7H-pyrazino[2,1-c]pyrido[3,2-e][1,4]oxazepine-3(4H)-carboxylic acid tert-butyl ester (Compound 8)
[0117] In a three-necked flask, compound 7 (17.6 g, 44.12 mmol, 1.0 eq.), tris(dibenzylideneacetone)dipalladium (1.21 g, 1.32 mmol, 0.03 eq.), 2-bicyclohexylphosphino-2',6'-diisopropoxybiphenyl (1.24 g, 2.66 mol, 0.06 q.), cesium carbonate (17.25 g, 52.94 mmol, 1.2 eq.), and dioxane (141 mL, 8 V) were added. The atmosphere was purged with nitrogen three times and stirred at 100-110°C until the reaction was complete. Ethyl acetate and water were added, and the organic phase was separated. Silica-based metal scavenger MS001 was added to the organic phase, stirred, filtered, and concentrated to obtain 19.74 g of compound 8 with a purity of 95.65%, which was used directly in the next reaction.
[0118] Example 7 Preparation of (R)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyrido[3,2-e][1,4]oxazepine-9-carboxamide dihydrochloride (Compound 9c)
[0119] In a flask, crude compound 8 (19.74 g) and methanol (127 mL, 6.5 V) were added and stirred to dissolve. 4N HCl / dioxane was added dropwise and stirred at room temperature until the reaction was complete. Concentration afforded 13.85 g of compound 9c, with a two-step yield of 93.6% and a purity of 98.48%.
[0120] Example 8 Preparation of (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyrido[3,2-e][1,4]oxazepine-9-carboxamide (Compound 11)
[0121] To a flask, compound 9c (13.0 g, 38.78 mmol, 1.0 eq.), compound 10 (8.63 g, 38.76 mmol, 1.0 eq.), sodium iodide (581 mg, 3.88 mmol, 0.1 eq.), N,N-dimethylformamide (43 mL, 5 V), and N,N-diisopropylethylamine (27.55 g, 213.16 mmol, 5.5 eq.) were added and stirred at 50-60°C until the reaction was complete. Water was added, the mixture was filtered, and dried to obtain 16.08 g of compound 11, with a yield of 92.4% and a purity of 97.75%.
[0122] Example 9 Preparation of (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyrido[3,2-e][1,4]oxazepine-9-carboxamide fumarate (Compound 12)
[0123] In a flask, compound 11 (15.48 g, 34.51 mmol, 1.0 eq.), fumaric acid (4.4 g, 37.91 mmol, 1.1 eq.), ethanol (464 mL, 30 V) and water (46 mL, 3 V) were added and stirred at 85-95 ° C until dissolved and clear. The mixture was filtered while hot and the filtrate was stirred at room temperature to precipitate a solid, which was filtered and dried to obtain 16.60 g of compound 12 with a yield of 85.2%, a purity of 99.22%, and a chiral purity of 100%.
Claims
1. A method for preparing a compound as shown in formula 7a or a pharmaceutically acceptable salt thereof, comprising reacting a compound as shown in formula 5a or a pharmaceutically acceptable salt thereof in the presence of carbon monoxide, a palladium catalyst and R4-NH2 to obtain a compound as shown in formula 7a or a pharmaceutically acceptable salt thereof, in, R1 is an amino protecting group; R2 is selected from halogen; R3 is selected from halogen; R4 is selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl; Each R5 is independently selected from halogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxy, cyano, oxo; Each R6 is independently selected from halogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxyl, cyano; n is an integer selected from 0 to 6; m is selected from an integer of 0-2.
2. The preparation method according to claim 1, wherein The palladium catalyst is selected from a divalent palladium catalyst, and preferably the palladium catalyst is selected from palladium acetate, palladium dichloride, tris(dibenzylideneacetone)dipalladium, bis(dibenzylideneacetone)palladium, palladium trifluoroacetate, palladium pivalate, tetrakis(triphenylphosphine)palladium, bis(triphenylphosphine)palladium chloride, bis(benzonitrile)palladium chloride, and bis(acetonitrile)palladium chloride.
3. The preparation method according to claim 1, wherein the molar ratio of the compound as represented by Formula 5a to the palladium catalyst is 1:0.1 to 1:0.0001; preferably 1:0.01 to 1:0.0005; more preferably 1:0.01 to 1:0.001, and most preferably 1:0.
005.
4. The preparation method according to claim 1, wherein The compound represented by Formula 5a or a pharmaceutically acceptable salt thereof is reacted in the presence of a phosphine ligand to obtain the compound represented by Formula 7a or a pharmaceutically acceptable salt thereof.
5. The preparation method according to claim 4, wherein The phosphine ligand is selected from triphenylphosphine, tri(o-methylphenyl)phosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2'-methylbiphenyl, 2-(di-tert-butylphosphino)-2'-methylbiphenyl, 1,1'-bis(diphenylphosphino)ferrocene, (±)-2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl, 4,5-bisdiphenylphosphino-9,9-dimethylxanthene, bis(2-diphenylphosphinophenyl)ether, 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino) ...6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2',6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)biphenyl, 2-(di-tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2',6'-triisopropylbiphenyl, 2-(dicyclohexylphosphino)biphenyl, 2-(di Phosphino-2'-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 2-(di-tert-butylphosphino)-3,6-dimethoxy-2'-4'-6'triisopropyl-1,1'-biphenyl, dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine, [(4-(N,N-dimethylamino)phenyl]di-tert-butylphosphine, 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropylbiphenyl, 1,2-bis(diphenylphosphino)ethane, 1,3-bis(diphenylphosphino)propane, 1,4-bis(diphenylphosphino)butane, preferably the phosphine ligand is 1,1'-bis(diphenylphosphino)ferrocene.
6. The preparation method according to claim 4, wherein The molar ratio of the compound represented by Formula 5a to the phosphine ligand is 1:0.1 to 1:0.0001; preferably 1:0.01 to 1:0.0005; more preferably 1:0.01 to 1:0.001; most preferably 1:0.
005.
7. The preparation method according to claim 1, wherein The compound represented by Formula 5a or a pharmaceutically acceptable salt thereof is reacted in the presence of a base to obtain the compound represented by Formula 7a or a pharmaceutically acceptable salt thereof.
8. The preparation method according to claim 7, wherein: The base is selected from sodium hydroxide, sodium carbonate, cesium carbonate, triethylamine, sodium acetate or pyridine.
9. The preparation method according to claim 7, wherein: The molar ratio of the compound represented by Formula 5a to the base is 1:5 to 1:0.5, preferably 1:5 to 1:1, more preferably 1:
2.
10. The preparation method according to claim 1, wherein: The R4 is selected from C 1-6 Alkyl, hydroxy C 1- 6 Alkyl, halogenated C 1-6 Alkyl, preferably R4 is selected from methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, halomethyl, haloethyl, halopropyl, halobutyl.
11. The preparation method according to claim 1, wherein: R1 is selected from C1-C6 alkyl acyl, C6-C 10 Aryl acyl, C1~C6 alkyl sulfonyl, C6~C 10 Arylsulfonyl, C1-C6 alkoxycarbonyl, C6-C 10 Aryloxycarbonyl, substituted or unsubstituted C7~C 12 Benzyl, preferably R1 is selected from formyl, acetyl, benzoyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn), more preferably R1 is tert-butyloxycarbonyl (Boc).
12. The preparation method according to claim 1, comprising reacting a compound as shown in Formula 5b or a pharmaceutically acceptable salt thereof to obtain a compound as shown in Formula 7b or a pharmaceutically acceptable salt thereof, 13. The preparation method according to claim 1, comprising reacting a compound as shown in Formula 5 or a pharmaceutically acceptable salt thereof to obtain a compound as shown in Formula 7 or a pharmaceutically acceptable salt thereof, 14. A method for preparing a compound of formula 8a or a pharmaceutically acceptable salt thereof, wherein: A method for preparing a compound as shown in formula 7a or a pharmaceutically acceptable salt thereof as claimed in claim 1, Wherein, R1, R3, R4, R5, R6, n, and m are as defined in claim 1.
15. The preparation method according to claim 14, comprising: The compound represented by Formula 7b or a pharmaceutically acceptable salt thereof is reacted to obtain the compound represented by Formula 8b or a pharmaceutically acceptable salt thereof, 16. The preparation method according to claim 14, comprising reacting the compound of formula 7 or a pharmaceutically acceptable salt thereof to obtain the compound of formula 8 or a pharmaceutically acceptable salt thereof, 17. A method for preparing a compound as shown in formula 11a or a pharmaceutically acceptable salt thereof, comprising (1) The compound as shown in 8a or a pharmaceutically acceptable salt thereof is prepared by the preparation method according to claim 14; (2) using the compound of formula 8a or a pharmaceutically acceptable salt thereof to prepare the compound of formula 11a or a pharmaceutically acceptable salt thereof; in, R1, R4, R5, R6, n, m are as defined in claim 1; R7 is selected from halogen; R8 is selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 Alkyl, preferably R8 is selected from methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, halomethyl, haloethyl, halopropyl, halobutyl.
18. A method for preparing a compound as shown in formula 11 or a pharmaceutically acceptable salt thereof, comprising (1) The compound as shown in 8 or a pharmaceutically acceptable salt thereof is prepared by the preparation method according to claim 16; (2) using the compound of Formula 8 or a pharmaceutically acceptable salt thereof to prepare the compound of Formula 11 or a pharmaceutically acceptable salt thereof;
Citation Information
Patent Citations
Method for preparing 2-aminobenzamide derivatives
CN103328434A
Method for preparing chlorantraniliprole intermediate K amine
CN115417781A
Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US5760232A
Substituted 1,6-naphthyridine inhibitors of CDK5
WO2022011274A1
Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
WO2022247816A1
Cited By
Naphthyridinone derivative and preparation method therefor
WO2026130518A1
